Better Health, Brighter Future

Over two centuries ago, a small medicine shop was opened in Doshomachi, Osaka, Japan to provide medicines to local merchants and doctors. This was the beginning of the present-day Takeda family of pharmaceutical companies. Now Takeda is Japan’s largest pharmaceutical company and one with a 230-year heritage. It is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. It also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines. It is focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging its enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
By acquisition of Shire In 2018, Takeda succeeded to hold a unique position in being a giant pharmaceutical company in the world with a focus on Rare Diseases acquired from Shire’s portfolio. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide.

In Iran Takeda is planning to launch the products of Adcetris which is used for the treatment of certain CD30-expressing Lymphomas and Entyvio which is a prescription medicine for appropriate adults with moderate to severe Ulcerative Colitis or Crohn’s disease.